This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mezzanzanica, D. Articles by Wunderlich, J. R. Search for Related Content PubMed Articles by Mezzanzanica, D. Articles by Wunderlich, J. R.

Human T-Lymphocytes Targeted against an Established Human Ovarian Carcinoma with a Bispecific F(ab')₂ Antibody Prolong Host Survival in a Murine Xenograft Model

Experimental Immunology Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892 [D. M., M. A. G., S. M. A., D. M. S. J. R. W.]; Centocor, Malvern, Pennsylvania 19355 [D. S. N., P. E. D., V. R. Z.]; and Department of Obstetrics and Gynecology, Harvard Medical School, Boston, Massachusetts 02115 [V. R. Z.]

A bispecific F(ab')₂ fragment with anti-CD3 and antitumor specificity was used to target activated human peripheral blood lymphocytes (PBL) against OVCAR-3 human ovarian carcinoma cells growing i.p. in athymic mice. Mice were given injections of OVCAR-3 cells on day 0 and treated with i.p. injections of activated PBL coated with the [anti-CD3 (TR66) x antitumor (MOv18)] bispecific F(ab')₂ on day 4, using an approximate effector:target ratio of 1:1. Treatment was evaluated for the ability either to block tumor growth at 15 days or to prolong survival of tumor-bearing mice. After 15 days, the incidence of mice with tumor growth was 20% among those given PBL coated with bispecific F(ab')₂, whereas the incidence among mice untreated or treated with PBL alone or PBL with either parental antibody ranged from 80 to 94%. The mean survival time of tumor-bearing mice treated with PBL and bispecific F(ab')₂ was 104 days, which was 3.5 times that of untreated mice and twice that of mice given PBL alone or PBL with either parental antibody. These results provide support for the concept that treatment of ovarian cancer patients with targeted T-cells could prove beneficial.

¹ Recipient of a fellowship from the Associazione Italiana per la Ricerca sul Cancro. Present address: Experimental Oncology E, Instituto Nazionale Tumori, 20133 Milan, Italy.

² To whom requests for reprints should be addressed.

Received 5/ 8/91. Accepted 8/ 6/91.

This article has been cited by other articles:

				M. Wu, W. Gunning, and M. Ratnam Expression of Folate Receptor Type {{alpha}} in Relation to Cell Type, Malignancy, and Differentiation in Ovary, Uterus, and Cervix Cancer Epidemiol. Biomarkers Prev., September 1, 1999; 8(9): 775 - 782. [Abstract] [Full Text]

				C Renner, W Jung, U Sahin, R Denfeld, C Pohl, L Trumper, F Hartmann, V Diehl, R van Lier, and M Pfreundschuh Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells Science, May 6, 1994; 264(5160): 833 - 835. [Abstract] [PDF]